No Data
No Data
Oxford Biomedica Names New Finance Chief
Oxford Biomedica (OXB.L) appointed Lucinda Crabtree as chief financial officer to succeed Stuart Paynter, effective Sept. 2.Crabtree previously held the CFO role in German biopharmaceutical company
MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger
MorphoSys (MOR.F) notified the Nasdaq Stock Market of its plan to delist from the Nasdaq Global Market, according to a July 12 filing.The German biopharmaceutical company intends to notify the
Press Release: MorphoSys Announces Voluntary Delisting From the Nasdaq Global Market
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--July 12, 2024-- MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has
MorphoSys AG Announces Merger Squeeze-Out
Novartis Seeks Squeeze Out Approval at MorphoSys AGM
The management board of MorphoSys (MOR.F) received a request from Novartis (NOVN.SW) to convene an annual general meeting on Aug. 27 to approve the transfer of the remaining shares of the Germany-
MorphoSys Announces Voluntary Delisting From the Nasdaq Global Market
EQS-News: MorphoSys AG / Key word(s): DelistingMorphoSys Announces Voluntary Delisting from the Nasdaq Global Market 12.07.2024 / 22:02 CET/CESTThe issuer is solely responsible for the content of
No Data
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long